Skip to content

    REGENERON PHARMACEUTICALS, INC.

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Trend
    EarningsRevenue
    $3.55B
    $3.72B
    $3.79B
    $3.03B
    $3.68B
    +3.6%
    $3.75B
    +0.9%
    $3.88B
    +2.5%
    $3.61B
    +19.0%
    Strengthening
    Operating Profit
    $1.07B
    $1.18B
    $990.20M
    $591.70M
    $1.08B
    +0.9%
    $1.03B
    -12.9%
    $879.90M
    -11.1%
    $642.90M
    +8.7%
    Weakening
    Net Profit
    $1.43B
    $1.34B
    $917.70M
    $808.70M
    $1.39B
    -2.8%
    $1.46B
    +8.9%
    $844.60M
    -8.0%
    $727.20M
    -10.1%
    Weakening
    EPS
    $13.25
    $12.40
    $7.58
    $13.24
    -0.1%
    $14.09
    +13.6%
    $6.99
    -7.8%
    Stable
    Other Income
    $558.50M
    $313.50M
    -$32.10M
    $313.30M
    $439.20M
    -21.4%
    $736.50M
    +134.9%
    $163.80M
    $188.30M
    -39.9%
    Strengthening
    Interest
    $14.80M
    $13.80M
    $10.50M
    $8.70M
    $3.60M
    -75.7%
    $19.30M
    +39.9%
    $12.20M
    +16.2%
    $12.90M
    +48.3%
    Strengthening
    Depreciation
    Profit before Tax
    $1.63B
    $1.49B
    $958.10M
    $905.00M
    $1.52B
    -6.7%
    $1.76B
    +18.1%
    $1.04B
    +8.9%
    $831.20M
    -8.2%
    Strengthening
    MarginsOPM
    30.1%
    31.7%
    26.1%
    19.5%
    29.4%
    -2.6%
    27.4%
    -13.7%
    22.6%
    -13.3%
    17.8%
    -8.8%
    Weakening
    Tax
    12.0%
    10.2%
    4.2%
    10.6%
    8.4%
    -30.4%
    17.2%
    +68.5%
    19.1%
    +352.1%
    12.5%
    +17.6%
    Strengthening
    ReturnsROIC
    4.7%
    4.4%
    3.0%
    2.6%
    4.5%
    -2.8%
    4.8%
    +8.9%
    2.8%
    -8.0%
    2.4%
    -10.1%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$1.47B$1.62B$2.19B$2.89B$3.11B$2.73B$2.49B$3.12B$2.96B
    Short-Term Investments$1.34B$1.60B$1.39B$2.81B$4.64B$8.11B$6.52B$5.49B$5.79B
    Total Current Assets$6.45B$7.69B$9.78B$14.01B$15.88B$19.48B$18.66B$18.02B$18.21B
    Net PP&E$2.58B$2.89B$3.22B$3.48B$3.83B$4.22B$4.82B$5.37B$5.27B
    Goodwill
    Intangibles$6.70M$915.50M$1.04B$1.15B$1.26B$1.29B
    Total Assets$11.73B$14.81B$17.16B$25.43B$29.21B$33.08B$37.76B$40.56B$40.87B
    LiabilitiesTotal Current Liabilities$1.44B$2.10B$2.70B$3.93B$3.14B$3.42B$3.94B$4.37B$5.11B
    Short-Term Debt$0
    Long-Term Debt$0$1.98B$1.98B$1.98B$1.98B$1.98B$1.99B$1.99B
    Long-Term Leases$55.80M$68.70M$204.10M$229.00M
    Total Liabilities$2.98B$3.72B$6.14B$6.67B$6.55B$7.11B$8.41B$9.30B$9.45B
    EquityCommon Stock & APIC
    Retained Earnings$5.25B$7.38B$10.89B$18.97B$23.31B$27.26B$31.67B$35.80B$36.42B
    Total Equity$8.76B$11.09B$11.03B$18.77B$22.66B$25.97B$29.35B$31.26B$31.42B
    HighlightsNet Cash / (Debt)$3.21B

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating$2.20B$2.43B$2.62B$7.08B$5.01B$4.59B$4.42B$4.98B$5.01B
    Cash from Investing-$1.46B-$2.03B-$70.60M-$5.38B-$3.78B-$3.19B-$2.47B-$629.10M-$1.71B
    Cash from Financing-$77.10M-$252.10M-$1.97B-$1.01B-$1.01B-$1.79B-$2.20B-$3.72B-$3.43B
    SummaryCapital Expenditure-$383.10M-$429.60M-$614.60M-$551.90M-$590.10M-$718.60M-$755.90M-$898.40M-$899.70M
    Free Cash Flow$1.81B$2.00B$2.00B$6.53B$4.42B$3.88B$3.66B$4.08B$4.11B
    FCF Margin35.2%30.5%23.6%40.6%36.3%29.5%25.8%28.4%27.6%